Alpha Cognition Inc. (ACOG)Healthcare | Biotechnology | Vancouver, Canada | NasdaqCM
6.70 USD
-0.19
(-2.758%) ⇩
(April 21, 2026, 10:23 a.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:09 a.m. EDT
Despite recent catalyst-driven rallies and a unified analyst 'Buy' rating, Alpha Cognition remains a long-term speculative hold weighed down by negative earnings, high valuation metrics (P/S ~15x), and negative operating cash flow; the short-term outlook is cautious due to poor momentum-adjustment statistics and the looming uncertainty of the upcoming earnings date. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.069555 |
| AutoTheta | 0.069826 |
| AutoETS | 0.069943 |
| AutoARIMA | 0.069943 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.54 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.913 |
| Excess Kurtosis | -0.07 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.578 |
| Market Cap | 145,886,496 |
| Forward P/E | -13.40 |
| Beta | 2.52 |
| Profit Margins | -202.24% |
| Previous Name | Crystal Bridge Enterprises Inc. |
| Website | https://www.alphacognition.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5109649 |
| Address1 | 750 West Pender Street |
| Address2 | Suite 1200 |
| All Time High | 11.54 |
| All Time Low | 3.75 |
| Ask | 7.13 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 66,410 |
| Average Daily Volume3 Month | 68,206 |
| Average Volume | 68,206 |
| Average Volume10Days | 66,410 |
| Beta | 2.521 |
| Bid | 6.59 |
| Bid Size | 1 |
| Book Value | 2.872 |
| City | Vancouver |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.7 |
| Current Ratio | 8.654 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 6.91 |
| Day Low | 6.69 |
| Display Name | Alpha Cognition |
| Earnings Call Timestamp End | 1,774,557,000 |
| Earnings Call Timestamp Start | 1,774,557,000 |
| Earnings Timestamp | 1,774,555,200 |
| Earnings Timestamp End | 1,778,788,800 |
| Earnings Timestamp Start | 1,778,788,800 |
| Ebitda | -22,602,116 |
| Ebitda Margins | -2.2115 |
| Enterprise To Ebitda | -3.715 |
| Enterprise To Revenue | 8.217 |
| Enterprise Value | 83,976,848 |
| Eps Current Year | -1.505 |
| Eps Forward | -0.5 |
| Eps Trailing Twelve Months | -1.18 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.851 |
| Fifty Day Average Change | 0.849 |
| Fifty Day Average Change Percent | 0.1451034 |
| Fifty Two Week Change Percent | 51.09649 |
| Fifty Two Week High | 11.54 |
| Fifty Two Week High Change | -4.84 |
| Fifty Two Week High Change Percent | -0.41941077 |
| Fifty Two Week Low | 4.31 |
| Fifty Two Week Low Change | 2.3899999 |
| Fifty Two Week Low Change Percent | 0.55452436 |
| Fifty Two Week Range | 4.31 - 11.54 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,731,421,800,000 |
| Float Shares | 11,032,721 |
| Forward Eps | -0.5 |
| Forward P E | -13.4 |
| Free Cashflow | -14,043,052 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.8126 |
| Gross Profits | 8,304,952 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.09794 |
| Held Percent Institutions | 0.52651 |
| Implied Shares Outstanding | 21,774,105 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-11-12 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada. |
| Long Name | Alpha Cognition Inc. |
| Market | us_market |
| Market Cap | 145,886,496 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_314597563 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-20 |
| Net Income To Common | -20,669,876 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 149,588,094 |
| Number Of Analyst Opinions | 2 |
| Open | 6.9 |
| Operating Cashflow | -20,380,368 |
| Operating Margins | -2.83747 |
| Payout Ratio | 0.0 |
| Phone | 604 564 9244 |
| Prev Name | Crystal Bridge Enterprises Inc. |
| Previous Close | 6.89 |
| Price Eps Current Year | -4.451827 |
| Price Hint | 2 |
| Price To Book | 2.332869 |
| Price To Sales Trailing12 Months | 14.274224 |
| Profit Margins | -2.02244 |
| Quick Ratio | 7.698 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.19000006 |
| Regular Market Change Percent | -2.7576206 |
| Regular Market Day High | 6.91 |
| Regular Market Day Low | 6.69 |
| Regular Market Day Range | 6.69 - 6.91 |
| Regular Market Open | 6.9 |
| Regular Market Previous Close | 6.89 |
| Regular Market Price | 6.7 |
| Regular Market Time | 1,776,781,417 |
| Regular Market Volume | 10,086 |
| Return On Assets | -0.21711001 |
| Return On Equity | -0.40679002 |
| Revenue Per Share | 0.578 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 21,774,104 |
| Shares Percent Shares Out | 0.015 |
| Shares Short | 327,498 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 317,725 |
| Short Name | Alpha Cognition Inc. |
| Short Percent Of Float | 0.015700001 |
| Short Ratio | 5.73 |
| Source Interval | 15 |
| State | BC |
| Symbol | ACOG |
| Target High Price | 18.0 |
| Target Low Price | 14.0 |
| Target Mean Price | 16.0 |
| Target Median Price | 16.0 |
| Total Cash | 66,046,788 |
| Total Cash Per Share | 3.033 |
| Total Debt | 0 |
| Total Revenue | 10,220,275 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.18 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.98945 |
| Two Hundred Day Average Change | -0.28945017 |
| Two Hundred Day Average Change Percent | -0.04141244 |
| Type Disp | Equity |
| Volume | 10,086 |
| Website | https://www.alphacognition.com |
| Zip | V6C 2T8 |